Anti-Rheumatic Rx
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
David Liew drdavidliew
1 year 7 months ago
As per #ACR23 ABST0433, what % of RA patients on US Medicare are on a DMARD within 1y of diagnosis?
I'm not talking your choice of b/tsDMARD.
I'm talking any cs/b/tsDMARD of any sort.
Hear from @JihaRheum to skip to the answer:
https://t.co/lI2M20JWKC
Truly stunning. @RheumNow
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
Janet Pope
1 year 7 months ago
#ACRbest Yrin Preview @ACRheum
J Bathon
Take home
Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c
AI to read joint erosions on X-ray May be ‘too little too late’
#Steroids in #RA increase #MACE even after d/c
#ACR23 @RheumNow
Richard Conway
1 year 7 months ago
Peng et al. 146 IgG4-RD in remission on immunomodulators+GC. 18 month follow-up. Withdraw IM+GC - 52% flare. Withdraw GC + continue IM 14.2% flare. Continue both 12.2% flare. Clear message that ongoing IM is the way Abstr#L16 #ACR23 #ACRbest @RheumNow https://t.co/3CAQhyTYqq https://t.co/qr1GOSvJYg
Eric Dein
1 year 7 months ago
L16 #ACR23 @RheumNow
W/d of Immunosuppr and Low-dose steroid in IgG4RD
Gr1: W/d GC+IM, G2: IM alone, G3: Maintain
Relapse rate: G1 52%, G2 14%, G3 12% https://t.co/xe6NLVxUov
Robert B Chao, MD
1 year 7 months ago
Withdrawing immunosuppression and steroids in IgG4-RD
Maintaining immunosuppression with or without steroids associated with low relapse rate
52% of pts who withdrew steroids +immunosuppression relapsed
@RheumNow #ACR23 Abs#L16 https://t.co/xJyDiCkMVD
Bella Mehta bella_mehta
1 year 7 months ago
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease
146 pts - 3 Grps
1: withdraw GC+IM 2:withdraw GC but maintain IM; 3: maintain GC+IM
The maintenance of IMs, with or without low-dose GC, superior to withdraw
#ACR23 @rheumnow #abstL16
Md Yuzaiful Md Yusof
1 year 7 months ago
#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest https://t.co/xUhoFHPExr
David Liew drdavidliew
1 year 7 months ago
Would intraarticular steroids for knee OA be better with a sustained release formulation?
ph3, TLL599 (liposomal delivery dexamethasone) vs normal dex vs placebo
some gains over normal dex
well tolerated
New options always welcome in OA!
@ProfDavidHunter #ACR23 L19 @RheumNow https://t.co/TUrhppHMiD
Eric Dein
1 year 7 months ago
L20 #ACR23 @RheumNow
Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response
ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001)
DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0
Better PROs, less jt damage prog at w24
Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW
Robert B Chao, MD
1 year 7 months ago
Sustained relief for knee OA
TLC599 - liposomal formulation of dexamethasone sodium phosphate
Single injection provided relief for 24 weeks, repeat injection with benefit up to wk 52
@RheumNow #ACR23 Abs#L19
#ACRBest https://t.co/BNGb3nHw8C
Md Yuzaiful Md Yusof
1 year 7 months ago
#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO.
+ve: less radiographic damage
-ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator
Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1
Poster Hall